Candel Therapeutics (NASDAQ: $CADL): Revolutionizing Glioma Treatment and Redefining Hope from ms excel to pdf Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 8:32 👁 View: 630K times ✓ Published: 12-Apr-2024
Description: Francesca Barone, CSO of Candel Therapeutics, was recently interviewed by Benzinga.<br/><br/>Candel is a clinical-stage biopharmaceutical company focused on developing immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The company has two main platforms that are currently undergoing clinical trials. <br/><br/>Ms. Barone spoke about the company's work in deadly brain cancers. Its candidate, CAN-3110, is currently undergoing phase 1 trials. It recently published exciting data from the trial showing promising results.
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)